GenMark Diagnostics, Inc. (GNMK) Shares Up 0% After Insider Buying Activity

For the current quarter Genmark Diagnostics (NASDAQ:GNMK) has high EPS estimates of $-0.22 in contradiction of low EPS estimates of $-0.32. GenMark Diagnostics, Inc. price was kept to a minimum $3.87 in intra-day trade and has returned -66.5% this year alone.

Among 12 analysts covering DaVita (NYSE:DVA), 1 have Buy rating, 3 Sell and 8 Hold. Zacks' sales averages are a mean average based on a survey of research firms that follow GenMark Diagnostics.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings results on Thursday, November 2nd. The Cadian Capital Management Lp holds 3.99 million shares with $47.15M value, up from 3.19 million last quarter. The business had revenue of $12.36 million during the quarter, compared to the consensus estimate of $12.44 million.

While having a peek at profitability ratios Genmark Diagnostics (NASDAQ:GNMK) has trailing twelve month gross margin at 51.7%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%. Over the trailing year, the stock is underperforming the S&P 500 by 21.11, and it's gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. The difference between the expected and actual EPS was $-0.05/share, which represents an Earnings surprise of -15.6%.

A number of research analysts have recently issued reports on GNMK shares. BidaskClub lowered GenMark Diagnostics from a "hold" rating to a "sell" rating in a research note on Wednesday, July 12th. Cowen and Company raised GenMark Diagnostics from a "market perform" rating to an "outperform" rating and set a $17.00 price target for the company in a research note on Friday, September 16th. They set a "buy" rating and a $13.00 price target on the stock. BTIG Research restated a "buy" rating and set a $13.00 price target on shares of GenMark Diagnostics in a research note on Thursday, August 31st. New York-based Needham Inv Mngmt Ltd has invested 0.16% in GenMark Diagnostics, Inc (NASDAQ:GNMK). One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Currently, the stock has a 1 Year Price Target of $14.36. Genmark Diagnostics Inc now has $254.66M valuation. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of USA and worldwide copyright & trademark legislation. About 176,123 shares traded or 796.67% up from the average. As per Monday, June 26, the company rating was maintained by RBC Capital Markets. HighTower Advisors LLC now owns 2,074,347 shares of the company's stock worth $24,477,000 after buying an additional 2,028,046 shares during the last quarter. Following the sale, the chief financial officer now directly owns 138,096 shares of the company's stock, valued at approximately $1,305,007.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Jennifer Anne Williams sold 38,681 shares of the stock in a transaction on Friday, September 15th. The shares were purchased at an average cost of $11.80 per share, with a total value of $23,600.00. Vanguard Group Inc Incorporated owns 2.17 million shares for 0% of their portfolio. The disclosure for this purchase can be found here. The company traded as high as $4.26 and last traded at $4.10. JPMorgan Chase & Co. boosted its holdings in shares of GenMark Diagnostics by 15.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,097,767 shares of the medical equipment provider's stock worth $48,476,000 after purchasing an additional 559,629 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of GenMark Diagnostics by 0.7% in the third quarter. The stock hit its twelve month high on 05/09/17, and twelve month low on 11/06/17. Insiders have sold 58,917 shares of company stock valued at $539,162 in the last quarter. Commercial Bank Of Ny Mellon Corporation has invested 0% of its portfolio in Perceptron, Inc. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions.



Latest news

Gen Jeep Wrangler interior revealed
Further down is the power window controls, and under that the drive modes for the four-wheel drive system. Most of this can also be handled by the UConnect system touchscreen at the top of the center stack.

Keith Urban Releases Uncompromising 'Female' Single
For a guy who grew up with no sisters in a house of boys, it's incredible how now I'm surrounded by girls. Now I am in a house that's all girls. "I am going to write songs", DiPiero said .

This Chinese Snapchat Competitor Just Bought $2B of Snap Stocks
Snap posted a $443.15 million net loss for the quarter, compared with $124.22 million in red ink in the year-ago period. UBS analyst Eric Sheridan downgraded Snap from neutral to sell, lowering the target share price from $12 to $7.

Square Inc (SQ) Q3 Profit And Revenue Top Expectations
Looking ahead, Square forecast Q4 EPS of $0.05 to $0.06, which is in-line with the $0.06 per share analysts are looking for. Net loss per share, basic and diluted, was $0.04, compared to a net loss per share of $0.09 in the third quarter of 2016.

Veterans Day Discounts, Deals And Freebies
Eat'n Park Restaurants are honoring all active and former US military personnel with a 10 percent discount through November 30. Texas Roadhouse - On Saturday November 11th, select from a free special veterans lunch menu including a beverage and sides.

Other news